Anavex Life Sciences Corp (AVXL)

[jimmy667]

RETT is genetic in origin so a cure will have to come from gene editing or gene silencing. A2-73 and all the others are just looking to provide some symptomatic and quality of life relief. Therefore these drugs do not compete as SOC but maybe complimentary to each other. Not like a SOC that would preclude a new antibiotic for pneumonia for instance unless the new drug was better. There are reasons that in the complicated spectrum of RETT as well as Epilepsy that there are not SOC drugs that preclude others from approval. The poster is possibly conflating the RETT situation to one they may have encountered in another situation as one would in the antibiotic field.
In RETT these various drugs if approved would likely be stacked and tailored to each patient in their multi drug regimen as now treated and as Parkinson's is currently treated.
Likely also A2-73 in PD if approved will be another drug in the Regimen.
However the importance of both these trial are they may prove A2-73 to be effective and establish the benefits of the MOA. Which might prove to be a useful in a great variety of applications much like modern Portland cement can be used in a great variety of building applications and a great improvement on the previous technology such as adobe or mud bricks which had limited application but previously had been the technology of one of Portland cement's applications.
It looks as though PDD will prove A2-73 MOA first unless there is dramatic results in the first fifteen RETT girls.